$100M to $250M is "sweet spot" for pharma venture funds

06/20/2013 | Genetic Engineering & Biotechnology News

Half of the 20 drugmaker venture capital funds on this list report total resources of between $100 million and $250 million. GlaxoSmithKline, Pfizer, Novartis, Sanofi, Merck and Boehringer Ingleheim are among the drugmakers starting or investing in venture capital funds for new drug discovery.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD